// App-Quantinova.ai

719 : Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors

Researchers

Presenter

  • Natalie Cook

Principal Investigators

  • Juanita Lopez

  • Debashis Sarker

  • Alastair Greystoke

  • Saira Bashir

  • Aglaia Skolariki

  • Salma ElBadri

  • Cienne Morton

  • Ana OrtegoFranco

  • Shybi MohamedKhan

  • Catherine Eagle

  • Eimear Flanagan

  • Louise Goodwin

  • Caroline Phillips

  • Jane Robertson

  • Craig Tilston

  • Helen Timmis

  • Simon Woodcock

  • Ruth Plummer

Medical Centers

  • Oxford University Hospital, Oxford,

  • Guy’s Hospital NHS Trust, London, UK

  • University of Manchester, The Christie, Manchester, UK

  • Royal Marsden Hospital, London,

  • Redx Pharma, Alderley Park, UK

  • The Freeman Hospital, Newcastle-upon-Tyne, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved